AlgoTherapeutix
Suresnes
About AlgoTherapeutix
AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy and adapting treatment to the very particular needs of the people afflicted. ATX01's admission into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy has been approved by the FDA. In the meanwhile, AlgoTx is investigating its potential in erythromelalgia, a rare and painful condition.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $37.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Mar 2023)
- Website: algotx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Information Technology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/algotherapeutix-46871 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.